Skip to content
2000
Volume 5, Issue 8
  • ISSN: 1386-2073
  • E-ISSN: 1875-5402

Abstract

Metabonomics is an emerging technology that enables rapid in vivo screening for toxicity, disease state, or drug efficacy. The technology combines the power of high-resolution nuclear magnetic resonance (NMR) techniques with statistical data analysis methods to rapidly evaluate the metabolic “status” of an animal. Complimentary to other profiling technologies like proteomics and genomics, metabonomics provides a fingerprint of the small-molecules contained in a given biofluid through the time course of a study. This article reviews the steps in implementing a metabonomics-based screening program from study design through data analysis. While metabonomics is still a relatively new technology in comparison to the other “omics”, published results from metabonomics studies demonstrate its potential impact in the drug discovery process by enabling the incorporation of safety endpoints much earlier in the drug discovery process, reducing the likelihood (and cost) of later stage attrition.

Loading

Article metrics loading...

/content/journals/cchts/10.2174/1386207023329932
2002-12-01
2025-06-26
Loading full text...

Full text loading...

/content/journals/cchts/10.2174/1386207023329932
Loading

  • Article Type:
    Review Article
Keyword(s): drug discovery; metabonomics; nmr; toxicity screening
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test